Share Price and Basic Stock Data
Last Updated: December 19, 2025, 10:06 pm
| PEG Ratio | 5.13 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Pharmalabs Ltd operates in the pharmaceutical sector, focusing on active pharmaceutical ingredients (APIs) and specialty chemicals. The company has shown a robust sales trajectory, with revenue reaching ₹1,946 Cr in FY 2023, a notable increase from ₹1,200 Cr in FY 2022. However, FY 2024 saw a dip in sales to ₹1,853 Cr, which raises questions about sustainability in growth. The latest figures for FY 2025 indicate a recovery, with sales reported at ₹2,115 Cr. This fluctuation suggests that while Aarti Pharmalabs is capable of strong revenue generation, it faces challenges in maintaining consistent performance quarter over quarter. The trailing twelve months (TTM) revenue of ₹1,946 Cr underscores the need for strategic initiatives to stabilize and enhance sales moving forward.
Profitability and Efficiency Metrics
When it comes to profitability, Aarti Pharmalabs has demonstrated commendable operating profit margins (OPM), which stood at 22% for FY 2025, up from 18% in FY 2023. The net profit for the same period was ₹272 Cr, reflecting an increase from ₹217 Cr in FY 2024, and a substantial rise from ₹193 Cr in FY 2023. This upward trend in profitability is further supported by a healthy return on equity (ROE) of 14.5% and a return on capital employed (ROCE) of 17.4%. However, the cash conversion cycle (CCC) remains at 200 days, which may seem stretched compared to industry standards. This extended CCC could potentially tie up working capital and affect liquidity, especially in times of economic uncertainty. Overall, while the company’s profitability metrics appear strong, the efficiency ratios warrant closer scrutiny.
Balance Sheet Strength and Financial Ratios
Aarti Pharmalabs exhibits a solid balance sheet with total reserves of ₹2,001 Cr and borrowings of ₹659 Cr, translating to a manageable debt-to-equity ratio of 0.19. This suggests that the company is not overly leveraged, which is a positive indicator for financial stability. The interest coverage ratio (ICR) of 17.64x further reinforces this strength, indicating that operating income comfortably covers interest expenses. However, the price-to-book value (P/BV) ratio of 3.41x may appear high, possibly reflecting investor optimism, but it also raises concerns about overvaluation. Furthermore, the company’s current ratio of 2.01 indicates a strong liquidity position, allowing it to meet short-term obligations without strain. Overall, while Aarti Pharmalabs displays a robust balance sheet, the high P/BV ratio and extended CCC are points of caution.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Pharmalabs reveals a diverse investor base, with promoters holding 42.88% as of the latest data. This is a slight decline from previous periods, indicating a potential shift in confidence among insiders. Foreign institutional investors (FIIs) account for 8.02%, while domestic institutional investors (DIIs) hold 6.95%. The public holds a significant 42.12%, with the total number of shareholders reported at 1,90,655. This broad distribution suggests a healthy level of public interest and potential market support. However, the declining promoter stake raises questions about insider confidence in the company’s future. Investors should closely monitor changes in shareholding patterns, as they can often signal shifts in strategic direction or management outlook.
Outlook, Risks, and Final Insight
The outlook for Aarti Pharmalabs appears cautiously optimistic, yet it is not without its risks. The company has demonstrated an ability to generate revenue and profit, but the volatility in sales figures and extended cash conversion cycle could pose challenges. Investors should be aware of the competitive landscape in pharmaceuticals, particularly as market dynamics shift. Regulatory hurdles and pricing pressures could impact profitability. Additionally, the declining promoter stake may indicate a lack of confidence in the company’s future growth trajectory. Aarti Pharmalabs has strengths in its profitability and balance sheet, but these must be weighed against potential risks. Investors might consider a watchful approach, looking for signs of stability and growth before making significant commitments to the stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.63 Cr | 1,151.80 | 52.58 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 457 | 531 | 472 | 485 | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 |
| Expenses | 371 | 441 | 385 | 405 | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 |
| Operating Profit | 86 | 90 | 86 | 80 | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 |
| OPM % | 19% | 17% | 18% | 16% | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% |
| Other Income | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 |
| Interest | 4 | 6 | 5 | 6 | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 |
| Depreciation | 14 | 17 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 |
| Profit before tax | 68 | 69 | 65 | 59 | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 |
| Tax % | 24% | 26% | 27% | 27% | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% |
| Net Profit | 52 | 51 | 48 | 43 | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 |
| EPS in Rs | 5.26 | 4.73 | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 |
Last Updated: August 20, 2025, 12:50 am
Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 386.00 Cr.. The value appears to be declining and may need further review. It has decreased from 564.00 Cr. (Mar 2025) to 386.00 Cr., marking a decrease of 178.00 Cr..
- For Expenses, as of Jun 2025, the value is 293.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 418.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 125.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 146.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 53.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 24.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 65.00 Cr., marking a decrease of 50.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 24.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 88.00 Cr. (Mar 2025) to 50.00 Cr., marking a decrease of 38.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.46. The value appears to be declining and may need further review. It has decreased from 9.75 (Mar 2025) to 5.46, marking a decrease of 4.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:21 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,906 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,651 | 1,464 |
| Operating Profit | 0 | 207 | 342 | 386 | 464 | 442 |
| OPM % | 17% | 18% | 21% | 22% | 23% | |
| Other Income | 0 | 3 | 2 | 5 | 10 | 5 |
| Interest | 0 | 12 | 21 | 17 | 27 | 34 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 93 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 319 |
| Tax % | 21% | 26% | 28% | 24% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 240 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 26.45 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 58.20% | 12.44% | 25.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -45.76% | 12.91% |
Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,001 |
| Borrowings | 0 | 341 | 215 | 285 | 413 | 659 |
| Other Liabilities | 0 | 312 | 470 | 540 | 503 | 561 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,515 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 160 |
| Investments | 0 | 32 | 87 | 107 | 77 | 187 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,319 | 1,403 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,906 | 3,266 |
Below is a detailed analysis of the balance sheet data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,001.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,945.00 Cr. (Mar 2025) to 2,001.00 Cr., marking an increase of 56.00 Cr..
- For Borrowings, as of Sep 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 413.00 Cr. (Mar 2025) to 659.00 Cr., marking an increase of 246.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 561.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 561.00 Cr., marking an increase of 58.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,266.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,137.00 Cr. (Mar 2025) to 1,515.00 Cr., marking an increase of 378.00 Cr..
- For CWIP, as of Sep 2025, the value is 160.00 Cr.. The value appears to be declining and may need further review. It has decreased from 374.00 Cr. (Mar 2025) to 160.00 Cr., marking a decrease of 214.00 Cr..
- For Investments, as of Sep 2025, the value is 187.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2025) to 187.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,403.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,319.00 Cr. (Mar 2025) to 1,403.00 Cr., marking an increase of 84.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,266.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,906.00 Cr. (Mar 2025) to 3,266.00 Cr., marking an increase of 360.00 Cr..
Notably, the Reserves (2,001.00 Cr.) exceed the Borrowings (659.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -134.00 | 127.00 | 101.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 115 | 84 | 102 | 99 | |
| Inventory Days | 272 | 188 | 230 | 190 | |
| Days Payable | 123 | 106 | 135 | 90 | |
| Cash Conversion Cycle | 264 | 166 | 197 | 200 | |
| Working Capital Days | 111 | 94 | 110 | 105 | |
| ROCE % | 19% | 16% | 17% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Multi Cap Fund | 428,834 | 0.15 | 30.05 | 428,834 | 2025-04-22 15:56:51 | 0% |
| ICICI Prudential Childrens Fund | 100,000 | 0.49 | 7.01 | N/A | N/A | N/A |
| ICICI Prudential Exports and Services Fund | 100,000 | 0.49 | 7.01 | N/A | N/A | N/A |
| Taurus Flexi Cap Fund | 72,058 | 1.38 | 5.05 | 59,058 | 2025-12-15 01:09:15 | 22.01% |
| HDFC Large and Mid Cap Fund | 67,500 | 0.02 | 4.73 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 10.00 |
| Basic EPS (Rs.) | 30.06 | 23.93 | 21.35 | 13.49 |
| Diluted EPS (Rs.) | 30.04 | 23.93 | 21.35 | 13.49 |
| Cash EPS (Rs.) | 39.64 | 32.01 | 28.25 | 36.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 219.55 | 193.88 | 171.97 | 304.30 |
| Revenue From Operations / Share (Rs.) | 233.36 | 204.42 | 214.64 | 263.36 |
| PBDIT / Share (Rs.) | 52.35 | 43.14 | 38.00 | 45.97 |
| PBIT / Share (Rs.) | 42.76 | 35.06 | 31.10 | 36.73 |
| PBT / Share (Rs.) | 39.80 | 33.16 | 28.77 | 34.10 |
| Net Profit / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| NP After MI And SOA / Share (Rs.) | 30.06 | 23.93 | 21.35 | 26.83 |
| PBDIT Margin (%) | 22.43 | 21.10 | 17.70 | 17.45 |
| PBIT Margin (%) | 18.32 | 17.14 | 14.48 | 13.94 |
| PBT Margin (%) | 17.05 | 16.21 | 13.40 | 12.94 |
| Net Profit Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| NP After MI And SOA Margin (%) | 12.87 | 11.70 | 9.94 | 10.18 |
| Return on Networth / Equity (%) | 13.68 | 12.34 | 12.41 | 8.81 |
| Return on Capital Employeed (%) | 17.23 | 16.83 | 17.19 | 11.46 |
| Return On Assets (%) | 9.37 | 8.40 | 8.67 | 5.99 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.15 | 0.13 | 0.24 |
| Asset Turnover Ratio (%) | 0.77 | 0.76 | 0.75 | 0.00 |
| Current Ratio (X) | 2.01 | 1.94 | 1.95 | 1.77 |
| Quick Ratio (X) | 1.12 | 1.01 | 0.93 | 0.95 |
| Inventory Turnover Ratio (X) | 3.44 | 1.38 | 1.78 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 11.64 | 8.35 | 10.04 | 2.02 |
| Dividend Payout Ratio (CP) (%) | 8.82 | 6.24 | 7.59 | 1.50 |
| Earning Retention Ratio (%) | 88.36 | 91.65 | 89.96 | 97.98 |
| Cash Earning Retention Ratio (%) | 91.18 | 93.76 | 92.41 | 98.50 |
| Interest Coverage Ratio (X) | 17.64 | 22.71 | 16.36 | 17.52 |
| Interest Coverage Ratio (Post Tax) (X) | 11.13 | 13.60 | 10.19 | 11.22 |
| Enterprise Value (Cr.) | 7172.16 | 4182.27 | 2678.01 | 0.00 |
| EV / Net Operating Revenue (X) | 3.39 | 2.26 | 1.38 | 0.00 |
| EV / EBITDA (X) | 15.12 | 10.70 | 7.78 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| Retention Ratios (%) | 88.35 | 91.64 | 89.95 | 97.97 |
| Price / BV (X) | 3.41 | 2.24 | 1.60 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.13 | 1.28 | 0.00 |
| EarningsYield | 0.04 | 0.05 | 0.07 | 0.00 |
After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For Diluted EPS (Rs.), as of Mar 25, the value is 30.04. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.04, marking an increase of 6.11.
- For Cash EPS (Rs.), as of Mar 25, the value is 39.64. This value is within the healthy range. It has increased from 32.01 (Mar 24) to 39.64, marking an increase of 7.63.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 233.36. It has increased from 204.42 (Mar 24) to 233.36, marking an increase of 28.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.35. This value is within the healthy range. It has increased from 43.14 (Mar 24) to 52.35, marking an increase of 9.21.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.76. This value is within the healthy range. It has increased from 35.06 (Mar 24) to 42.76, marking an increase of 7.70.
- For PBT / Share (Rs.), as of Mar 25, the value is 39.80. This value is within the healthy range. It has increased from 33.16 (Mar 24) to 39.80, marking an increase of 6.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
- For PBDIT Margin (%), as of Mar 25, the value is 22.43. This value is within the healthy range. It has increased from 21.10 (Mar 24) to 22.43, marking an increase of 1.33.
- For PBIT Margin (%), as of Mar 25, the value is 18.32. This value is within the healthy range. It has increased from 17.14 (Mar 24) to 18.32, marking an increase of 1.18.
- For PBT Margin (%), as of Mar 25, the value is 17.05. This value is within the healthy range. It has increased from 16.21 (Mar 24) to 17.05, marking an increase of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 12.87. This value exceeds the healthy maximum of 10. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.68. This value is below the healthy minimum of 15. It has increased from 12.34 (Mar 24) to 13.68, marking an increase of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.23. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 17.23, marking an increase of 0.40.
- For Return On Assets (%), as of Mar 25, the value is 9.37. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 9.37, marking an increase of 0.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.19, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has increased from 0.76 (Mar 24) to 0.77, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.01, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.12, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.44, marking an increase of 2.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.64. This value is below the healthy minimum of 20. It has increased from 8.35 (Mar 24) to 11.64, marking an increase of 3.29.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 6.24 (Mar 24) to 8.82, marking an increase of 2.58.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.36. This value exceeds the healthy maximum of 70. It has decreased from 91.65 (Mar 24) to 88.36, marking a decrease of 3.29.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 91.18, marking a decrease of 2.58.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 22.71 (Mar 24) to 17.64, marking a decrease of 5.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.13. This value is within the healthy range. It has decreased from 13.60 (Mar 24) to 11.13, marking a decrease of 2.47.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,172.16. It has increased from 4,182.27 (Mar 24) to 7,172.16, marking an increase of 2,989.89.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.26 (Mar 24) to 3.39, marking an increase of 1.13.
- For EV / EBITDA (X), as of Mar 25, the value is 15.12. This value exceeds the healthy maximum of 15. It has increased from 10.70 (Mar 24) to 15.12, marking an increase of 4.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 88.35. This value exceeds the healthy maximum of 70. It has decreased from 91.64 (Mar 24) to 88.35, marking a decrease of 3.29.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 24) to 3.41, marking an increase of 1.17.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Pharmalabs Ltd:
- Net Profit Margin: 12.87%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.23% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.68% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.2 (Industry average Stock P/E: 43.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.87%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No 22/C/1 & 22/C/2, Vapi Gujarat 396195 | investorrelations@aartipharmalabs.com http://www.aartipharmalabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant Vallabhaji Gogri | Chairman Emeritus |
| Mr. Rashesh C Gogri | Chairman & Non-Exe.Director |
| Mrs. Hetal Gogri Gala | Vice Chairperson & M.D |
| Mr. Narendra J Salvi | Managing Director |
| Mr. Rajendra V Gogri | Non Executive Director |
| Mr. Parimal H Desai | Non Executive Director |
| Ms. Nehal Garewal | Non Executive Director |
| Mr. Bhavesh R Vora | Independent Director |
| Mrs. Jeenal K Savla | Independent Director |
| Mrs. Rupal A Vora | Independent Director |
| Mr. Vilas Gajanan Gaikar | Independent Director |
| Dr. Vinay G Nayak | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
FAQ
What is the intrinsic value of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd's intrinsic value (as of 19 December 2025) is 744.24 which is 0.37% lower the current market price of 747.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 6,757 Cr. market cap, FY2025-2026 high/low of 972/557, reserves of ₹2,001 Cr, and liabilities of 3,266 Cr.
What is the Market Cap of Aarti Pharmalabs Ltd?
The Market Cap of Aarti Pharmalabs Ltd is 6,757 Cr..
What is the current Stock Price of Aarti Pharmalabs Ltd as on 19 December 2025?
The current stock price of Aarti Pharmalabs Ltd as on 19 December 2025 is 747.
What is the High / Low of Aarti Pharmalabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Pharmalabs Ltd stocks is 972/557.
What is the Stock P/E of Aarti Pharmalabs Ltd?
The Stock P/E of Aarti Pharmalabs Ltd is 28.2.
What is the Book Value of Aarti Pharmalabs Ltd?
The Book Value of Aarti Pharmalabs Ltd is 226.
What is the Dividend Yield of Aarti Pharmalabs Ltd?
The Dividend Yield of Aarti Pharmalabs Ltd is 0.67 %.
What is the ROCE of Aarti Pharmalabs Ltd?
The ROCE of Aarti Pharmalabs Ltd is 17.4 %.
What is the ROE of Aarti Pharmalabs Ltd?
The ROE of Aarti Pharmalabs Ltd is 14.5 %.
What is the Face Value of Aarti Pharmalabs Ltd?
The Face Value of Aarti Pharmalabs Ltd is 5.00.